SIGA Technologies, Inc.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Its primary product is TPOXX, an antiviral drug used for the treatment of human smallpox disease caused by the variola virus. The company operates in the United States and is headquartered in New York, New York. SIGA's work is critical for public health preparedness, as smallpox is a highly contagious and deadly disease. The company was incorporated in 1995 and has since dedicated its efforts to developing therapies for biological threats. TPOXX is the only FDA-approved treatment for smallpox, making SIGA a key player in biodefense.

SIGA Technologies, Inc. is listed on the NasdaqGM exchange under the ticker symbol SIGA. The company trades in US Dollars (USD), as it is headquartered in the United States. Being listed on Nasdaq provides the company with visibility among investors interested in the healthcare and biodefense sectors. The stock is part of the broader US equity market, and its performance is influenced by factors such as government contracts, regulatory approvals, and public health concerns. Investors can trade SIGA shares during regular market hours on Nasdaq.

SIGA Technologies operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and production of specialized pharmaceutical products, particularly those that are not widely available as generics. In SIGA's case, its focus is on antiviral drugs for rare but severe infectious diseases like smallpox. The specialty drug manufacturer category includes companies that target niche therapeutic areas, often with high barriers to entry due to regulatory requirements. SIGA's work in biodefense aligns with this industry, as it addresses a specific public health need.

SIGA Technologies, Inc. is headquartered in New York, New York, United States. The company primarily serves the health security market in the United States. Its main customer is the U.S. government, which has procured TPOXX for the Strategic National Stockpile to ensure preparedness in the event of a smallpox outbreak. While SIGA's focus is domestic, its product has global implications for biodefense. The company's operations are centered in the U.S., and it does not have significant international sales reported in its summary. The New York headquarters houses its corporate and research functions.

SIGA Technologies' lead product is TPOXX (tecovirimat), an antiviral drug approved for the treatment of human smallpox disease caused by variola virus. The company generates revenue primarily through government contracts, especially with the U.S. Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense. These contracts involve the procurement of TPOXX for the Strategic National Stockpile. Additionally, SIGA may earn revenue from international government sales and potential commercial sales, though its current focus is on fulfilling U.S. government orders. The company's business model relies on securing and delivering large-scale orders for public health preparedness.